No abstract

A255 criteria, of which 3,152 (15.1%) underwent additional diagnostic imaging in the 6 months post-index. White women were 1.12 times more likely to be recalled than African-American women (p< 0.001). Average costs per patient recalled were $838 among white women and $804 among African-American women. Overall, 28.6% of costs were from additional imaging (diagnostic mammography and/or ultrasound), 39.2% were from guided biopsy procedures, and 24.4% from open biopsy. Recall-related office visits, MRI, fine needle aspiration, and ductogram accounted for < 5% of recall costs. Individual recall procedure rates were substantively similar between White and African-American recalled patients but African-American women had higher per-patient imaging costs and lower per-patient open biopsy costs. CONCLUSIONS: Improving breast cancer screening with a more accurate mammogram may significantly reduce Medicaid costs as approximately one-in-six women undergo additional diagnostic imaging following a screening mammogram with substantial associated costs. Recall rate and costs varied by race.

history of breast or ovarian cancer than BRCAwt (55.6% vs. 14.7%), [P=0.003]. Numerically lower GHS scores were reported in patients with BRCAm (mean EQ-5D overall index score=0.7 [SD: 0.2], mean VAS score=53.6 [SD: 18.1]) relative to BRCAwt (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score= 58.7 [SD: 22.4]) and BRCAunk (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score=67.7 [SD: 20.5]) patients. Conclusions: In this study, adult females with HER2-ABC, patients with BRCAm vs. BRCAwt were significantly younger and more likely to have a family history of breast or ovarian cancer. Numerically worse GHS scores were observed in patients with BRCAm relative to BRCAwt/BRCAunk. Future larger studies are warranted to validate these conclusions.

history of breast or ovarian cancer than BRCAwt (55.6% vs. 14.7%), [P=0.003]. Numerically lower GHS scores were reported in patients with BRCAm (mean EQ-5D overall index score=0.7 [SD: 0.2], mean VAS score=53.6 [SD: 18.1]) relative to BRCAwt (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score= 58.7 [SD: 22.4]) and BRCAunk (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score=67.7 [SD: 20.5]) patients. Conclusions: In this study, adult females with HER2-ABC, patients with BRCAm vs. BRCAwt were significantly younger and more likely to have a family history of breast or ovarian cancer. Numerically worse GHS scores were observed in patients with BRCAm relative to BRCAwt/BRCAunk. Future larger studies are warranted to validate these conclusions.

history of breast or ovarian cancer than BRCAwt (55.6% vs. 14.7%), [P=0.003]. Numerically lower GHS scores were reported in patients with BRCAm (mean EQ-5D overall index score=0.7 [SD: 0.2], mean VAS score=53.6 [SD: 18.1]) relative to BRCAwt (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score= 58.7 [SD: 22.4]) and BRCAunk (mean EQ-5D overall index score=0.8 [SD: 0.2], mean VAS score=67.7 [SD: 20.5]) patients. Conclusions: In this study, adult females with HER2-ABC, patients with BRCAm vs. BRCAwt were significantly younger and more likely to have a family history of breast or ovarian cancer. Numerically worse GHS scores were observed in patients with BRCAm relative to BRCAwt/BRCAunk. Future larger studies are warranted to validate these conclusions.